In and out of the niche: Perspectives in mobilization of hematopoietic stem cells

Experimental Hematology

Volumn 39, Issue 7, 2011, Pages 723-729

  Mohty, Mohamad ^a,b,c   Ho, Anthony D ^d  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Groupe Cytokines et Récepteurs   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CD38 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; PLACEBO; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1ALPHA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER STEM CELL; CELL COUNT; CELL FUNCTION; CELL INTERACTION; CELL PROTECTION; CELL SUBPOPULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; ENGRAFTMENT; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; LEUKEMIA CELL; MULTIPLE MYELOMA; NEUTROPHIL; NIGHTMARE; NONHODGKIN LYMPHOMA; NONHUMAN; PARESTHESIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; STEM CELL MOBILIZATION; THROMBOCYTE;

BONE MARROW CELLS; CHEMOKINE CXCL12; DRUG SYNERGISM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECEPTORS, CXCR4; STEM CELL NICHE;

EID: 79960568675     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.05.004     Document Type: Review

References (54)

1. Korbling M., Dorken B., Ho A.D., et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986, 67:529-532.
2. Reiffers J., Bernard P., David B., et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 1986, 14:312-315.
3. To L.B., Dyson P.G., Branford A.L., et al. Peripheral blood stem cells collected in very early remission produce rapid and sustained autologous haemopoietic reconstitution in acute non-lymphoblastic leukaemia. Bone Marrow Transplant 1987, 2:103-108.
4. Bell A.J., Figes A., Oscier D.G., Hamblin T.J. Peripheral blood stem cell autografts in the treatment of lymphoid malignancies: initial experience in three patients. Br J Haematol 1987, 66:63-68.
5. Kessinger A., Armitage J.O., Landmark J.D., Smith D.M., Weisenburger D.D. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988, 71:723-727.
6. Beyer J., Schwella N., Zingsem J., et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995, 13:1328-1335.
7. Schmitz N., Linch D.C., Dreger P., et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996, 347:353-357.
8. Hartmann O., Le Corroller A.G., Blaise D., et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997, 126:600-607.
9. Weaver C.H., Hazelton B., Birch R., et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995, 86:3961-3969.
10. Bensinger W., Appelbaum F., Rowley S., et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995, 13:2547-2555.
11. To L.B., Haylock D.N., Simmons P.J., Juttner C.A. The biology and clinical uses of blood stem cells. Blood 1997, 89:2233-2258.
12. Mohle R., Bautz F., Rafii S., et al. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998, 91:4523-4530.
13. Lapidot T., Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002, 30:973-981.
14. Petit I., Szyper-Kravitz M., Nagler A., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002, 3:687-694.
15. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
16. Cashen A.F., Nervi B., DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncol 2007, 3:19-27.
17. Philip T., Armitage J.O., Spitzer G., et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987, 316:1493-1498.
18. Rohatiner A.Z., Nadler L., Davies A.J., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007, 25:2554-2559.
19. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91-97.
20. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
21. Juttner C.A., To L.B., Ho J.Q., et al. Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia. Transplant Proc 1988, 20:40-42.
22. Corringham R.E., Ho A.D. Rapid and sustained allogeneic transplantation using immunoselected CD34(+)-selected peripheral blood progenitor cells mobilized by recombinant granulocyte- and granulocyte-macrophage colony-stimulating factors. Blood 1995, 86:2052-2054.
23. Korbling M., Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood 2001, 98:2900-2908.
24. Civin C.I., Strauss L.C., Brovall C., et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984, 133:157-165.
25. Gianni A.M., Siena S., Bregni M., et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989, 2:580-585.
26. Haas R., Ho A.D., Bredthauer U., et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1990, 18:94-98.
27. Elias A.D., Ayash L., Anderson K.C., et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992, 79:3036-3044.
28. Bensinger W., Singer J., Appelbaum F., et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993, 81:3158-3163.
29. Haas R., Mohle R., Fruhauf S., et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994, 83:3787-3794.
30. Sugrue M.W., Williams K., Pollock B.H., et al. Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000, 39:509-519.
31. Tarella C., Di Nicola M., Caracciolo D., et al. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant 2002, 30:725-732.
32. Gordan L.N., Sugrue M.W., Lynch J.W., et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003, 44:815-820.
33. Kuittinen T., Nousiainen T., Halonen P., Mahlamaki E., Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004, 33:907-912.
34. Pavone V., Gaudio F., Console G., et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:719-724.
35. Akhtar S., Weshi A.E., Rahal M., et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008, 49:769-778.
36. Pusic I., Jiang S.Y., Landua S., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.
37. Hosing C., Saliba R.M., Ahlawat S., et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009, 84:335-337.
38. Fruehauf S., Haas R., Conradt C., et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 1995, 85:2619-2626.
39. Fruehauf S., Schmitt K., Veldwijk M.R., et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 1999, 105:786-794.
40. Ho A.D., Wagner W. The beauty of asymmetry: asymmetric divisions and self-renewal in the haematopoietic system. Curr Opin Hematol 2007, 14:330-336.
41. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003, 2:581-587.
42. Mohty M., Duarte R.F., Croockewit S., et al. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 2011, 25:1-6.
43. Burroughs L., Mielcarek M., Little M.T., et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005, 106:4002-4008.
44. Larochelle A., Krouse A., Metzger M., et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006, 107:3772-3778.
45. Liles W.C., Broxmeyer H.E., Rodger E., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102:2728-2730.
46. Liles W.C., Rodger E., Broxmeyer H.E., et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005, 45:295-300.
47. Devine S.M., Flomenberg N., Vesole D.H., et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004, 22:1095-1102.
48. Flomenberg N., Devine S.M., Dipersio J.F., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106:1867-1874.
49. Stiff P., Micallef I., McCarthy P., et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009, 15:249-256.
50. Cashen A., Lopez S., Gao F., et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:1253-1261.
51. Calandra G., McCarty J., McGuirk J., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
52. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
53. DiPersio J.F., Micallef I.N., Stiff P.J., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
54. Wuchter P., Ran D., Bruckner T., et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010, 16:490-499.